REG - Morgan Stanley & Co. Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda

Takeda Pharmaceutical CoAnnouncement

09/01/2019 13:55

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190108:nRSH6568Ma

RNS Number : 6568M
Morgan Stanley & Co. Int'l plc
09 January 2019
 
AMENDMENT      Section (2a & 2b)
 
 FORM 8.5 (EPT/RI)
 
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED
INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 
 (a) Name of exempt principal trader:                                            Morgan Stanley & Co. International plc
 (b) Name of offeror/offeree in relation to whose relevant securities this form  Takeda Pharmaceutical Company Limited
 relates:
      Use a separate form for each offeror/offeree
 (c) Name of the party to the offer with which exempt principal trader is        Shire plc
 connected:
 (d) Date dealing undertaken:                                                    07 JANUARY 2019
 (e) In addition to the company in 1(b) above, is the exempt principal trader    Yes - Shire plc
 making disclosures in respect of any other party to this offer?
      If it is a cash offer or possible cash offer, state "N/A"
 
2.         DEALINGS BY THE EXEMPT PRINCIPAL TRADER
 
Where there have been dealings in more than one class of relevant securities
of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as
appropriate) for each additional class of relevant security dealt in.
 
 The currency of all prices and other monetary amounts should be stated.
 
 
(a)        Purchases and sales
 
  Class of    Purchases/    Total number    Highest price            Lowest price
 relevant    sales         of securities   per unit paid/received   per unit paid/received
 security
  Ordinary    PURCHASES     509,317         4,074.0000 JPY           3,908.0000 JPY
  Ordinary    SALES         491,717         4,074.0000 JPY           3,923.0000 JPY
  Ordinary    PURCHASES     49,600          36.8971 USD              36.7058 USD
 
 
(b)        Cash-settled derivative transactions
 
  Class of    Product description               Nature of dealing                                                              Number of reference securities    Price per
 relevant                e.g. CFD              e.g. opening/closing a long/short position, increasing/reducing a long/short                                     unit
                                             position
 security
  N/A         N/A                               N/A                                                                            N/A                               N/A
 
 
(c)        Stock-settled derivative transactions (including options)
 
(i)         Writing, selling, purchasing or varying
 
 Class of             Product description e.g. call option    Writing, purchasing, selling, varying etc.    Number of securities to which option relates    Exercise price per unit    Type   e.g. American, European etc.      Expiry date    Option money paid/ received per unit
 relevant security
  N/A                 N/A                                     N/A                                           N/A                                             N/A                        N/A                                      N/A            N/A
 
(ii)        Exercise
 
  Class of    Product description    Exercising/    Number of securities    Exercise price
 relevant    e.g. call option       exercised                              per unit
 security                           against
  N/A         N/A                    N/A            N/A                     N/A
 
(d)        Other dealings (including subscribing for new securities)
 
  Class of relevant security    Nature of dealing               Details    Price per unit (if applicable)
                               e.g. subscription, conversion
  N/A                           N/A                             N/A        N/A
 
 
3.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 
 Details of any indemnity or option arrangement, or any agreement or
 understanding,
 formal or informal, relating to relevant securities which may be an inducement
 to deal
 or refrain from dealing entered into by the exempt principal trader making the
 disclosure and any party to the offer or any person acting in concert with a
 party to the offer:
 Irrevocable commitments and letters of intent should not be included.  If
 there are no such agreements, arrangements or understandings, state "none"
 NONE
 
 
 (b)       Agreements, arrangements or understandings relating to
options or derivatives
 
 Details of any agreement, arrangement or understanding, formal or informal,
 between
 the exempt principal trader making the disclosure and any other person
 relating to:
 (i)  the voting rights of any relevant securities under any option; or
 (ii) the voting rights or future acquisition or disposal of any relevant
 securities to which any derivative is referenced:
 If there are no such agreements, arrangements or understandings, state "none"
 NONE
 
 
  Date of disclosure:    09 JANUARY 2019
  Contact name:          Craig Horsley
  Telephone number:      +44(141) 245 7736
 
Public disclosures under Rule 8 of the Code must be made to a Regulatory
Information Service.
 
The Panel's Market Surveillance Unit is available for consultation in relation
to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
(http://www.thetakeoverpanel.org.uk) .
 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.